Literature DB >> 20963641

Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer.

Nilufer Bulut1, Sercan Aksoy, Omer Dizdar, Didem S Dede, Cagatay Arslan, Erkan Dogan, Ibrahim Gullu, Yavuz Ozisik, Kadri Altundag.   

Abstract

We investigate retrospectively the demographic and clinico-pathological characteristics of patients with triple-negative breast cancer (TNBC) compared to those with non-TNBC. Patients with breast cancer diagnosed from 1981 to 2008 in our clinic were retrospectively analyzed. Patient demographics including survival data and tumor characteristics were obtained from charts. A total of 795 patients were assessed in the study, including 140 patients (17.6%) with TNBC and 655 patients (82.4%) with non-TNBC. Patients with non-TNBC were further classified into 3 groups according to hormone receptor (HR) and HER-2 status. Median age was 49 (range 38-60 years) and similar between patients with TNBC and non-TNBC. Patients with TNBC had an increased likelihood of a higher histological grade III compared with HR(+) HER-2(-) subgroup (P > 0.001) and lower stage compared with HR(+)/HER2(+) and HR(-)/HER2(+) subgroups (P < 0.001 and P = 0.002, respectively). In patients with TNBC, the disease-free survival (DFS) rate was 66% at 5 years. In subgroup analysis of non-TNBCs, 5-year-DFS rates of the patients in HR(+)/HER2(-), HR(+)/HER2(+) and HR(-)/HER2(+) subgroups were 59, 66, and 57%, respectively. There was no significant difference between the TNBC and non-TNBC subgroups (P = 0.238). In multivariate analysis, nodal involvement (RR = 2.8, 95% CI: 0.99-8.3, P = 0.052) and the presence of lymphovascular invasion (RR = 3.2, 95% CI: 1.1-9.2, P = 0.029) were significantly associated with increased recurrence risk in patients with TNBC. Although there are differences in patient and tumor features, patients with TNBC had similar clinical course with those with non-TNBC.

Entities:  

Mesh:

Year:  2010        PMID: 20963641     DOI: 10.1007/s12032-010-9715-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  15 in total

Review 1.  Triple-negative breast cancer.

Authors:  Gert Stockmans; Karen Deraedt; Hans Wildiers; Philippe Moerman; Robert Paridaens
Journal:  Curr Opin Oncol       Date:  2008-11       Impact factor: 3.645

2.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Authors:  Chad A Livasy; Gamze Karaca; Rita Nanda; Maria S Tretiakova; Olufunmilayo I Olopade; Dominic T Moore; Charles M Perou
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

3.  Differences in risk factors for breast cancer molecular subtypes in a population-based study.

Authors:  Xiaohong R Yang; Mark E Sherman; David L Rimm; Jolanta Lissowska; Louise A Brinton; Beata Peplonska; Stephen M Hewitt; William F Anderson; Neonila Szeszenia-Dabrowska; Alicja Bardin-Mikolajczak; Witold Zatonski; Richard Cartun; Daniza Mandich; Grzegorz Rymkiewicz; Marcin Ligaj; Stanislaw Lukaszek; Radzisaw Kordek; Montserrat García-Closas
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-03       Impact factor: 4.254

Review 4.  Pharmacotherapy of triple-negative breast cancer.

Authors:  Cagatay Arslan; Omer Dizdar; Kadri Altundag
Journal:  Expert Opin Pharmacother       Date:  2009-09       Impact factor: 3.889

5.  Pattern of metastatic spread in triple-negative breast cancer.

Authors:  Rebecca Dent; Wedad M Hanna; Maureen Trudeau; Ellen Rawlinson; Ping Sun; Steven A Narod
Journal:  Breast Cancer Res Treat       Date:  2008-06-10       Impact factor: 4.872

6.  Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.

Authors:  Ben Van Calster; Isabelle Vanden Bempt; Maria Drijkoningen; Nathalie Pochet; Jiqiu Cheng; Sabine Van Huffel; Wouter Hendrickx; Julie Decock; Huei-Jean Huang; Karin Leunen; Frederic Amant; Patrick Berteloot; Robert Paridaens; Hans Wildiers; Erik Van Limbergen; Caroline Weltens; Dirk Timmerman; Toon Van Gorp; Ann Smeets; Walter Van den Bogaert; Ignace Vergote; Marie-Rose Christiaens; Patrick Neven
Journal:  Breast Cancer Res Treat       Date:  2008-02-09       Impact factor: 4.872

Review 7.  What is triple-negative breast cancer?

Authors:  William J Irvin; Lisa A Carey
Journal:  Eur J Cancer       Date:  2008-11-12       Impact factor: 9.162

8.  Triple negative breast carcinoma is a prognostic factor in Taiwanese women.

Authors:  Che Lin; Su-Yu Chien; Li-Sheng Chen; Shou-Jen Kuo; Tsai-Wang Chang; Dar-Ren Chen
Journal:  BMC Cancer       Date:  2009-06-18       Impact factor: 4.430

Review 9.  Triple negative tumours: a critical review.

Authors:  J S Reis-Filho; A N J Tutt
Journal:  Histopathology       Date:  2008-01       Impact factor: 5.087

10.  Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.

Authors:  Marc Tischkowitz; Jean-Sébastien Brunet; Louis R Bégin; David G Huntsman; Maggie C U Cheang; Lars A Akslen; Torsten O Nielsen; William D Foulkes
Journal:  BMC Cancer       Date:  2007-07-24       Impact factor: 4.430

View more
  6 in total

1.  The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience.

Authors:  Yeşim Eralp; Leyla Kılıç; Gül Alço; Gül Başaran; Mutlu Doğan; Dilek Dinçol; Senem Demirci; Fikri İçli; Handan Onur; Pınar Saip; Ayfer Haydaroğlu
Journal:  J Breast Health       Date:  2014-10-01

2.  Does estrogen receptor determination affect prognosis in early stage breast cancers?

Authors:  Nilufer Bulut; Kadri Altundag
Journal:  Int J Clin Exp Med       Date:  2015-11-15

3.  Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer.

Authors:  Gilda Schmidt; Christoph Gerlinger; Ingolf Juhasz-Böss; Elmar Stickeler; Achim Rody; Cornelia Liedtke; Pauline Wimberger; Theresa Link; Eberhard Müller; Tanja Fehm; Manuela Abel; Stefan Stein; Rainer Bohle; Jan Endrikat; Erich-Franz Solomayer
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-23       Impact factor: 4.553

4.  New criteria to predict tumor recurrence in invasive ductal carcinoma of the breast.

Authors:  Tadahiro Nozoe; Emiko Mori; Tomohiro Iguchi; Takahiro Ezaki
Journal:  Int Surg       Date:  2013 Oct-Dec

5.  Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients.

Authors:  Katarzyna Pogoda; Anna Niwińska; Magdalena Murawska; Tadeusz Pieńkowski
Journal:  Med Oncol       Date:  2013-01-05       Impact factor: 3.064

6.  Racial disparities in survival and age-related outcome in postsurgery breast cancer patients in a new york city community hospital.

Authors:  Stacey Martindale; Awinder Singh; Hua Wang; Ashley Steinberg; Amer Homsi; Haidi Zhang; Alan Go; Peter Pappas
Journal:  ISRN Oncol       Date:  2014-02-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.